Business Context and Reporting Period
Company: Ascendis Pharma A/S
Filing Type: Form 6-K (Unaudited Condensed Consolidated Interim Financial Statements)
Reporting Period: Nine months ended September 30, 2025
Business Overview: A global biopharmaceutical company focused on its TransCon technology platform. Key commercial products include SKYTROFA (growth hormone deficiency) and YORVIPATH (hypoparathyroidism). The company is also advancing oncology candidates and strategic collaborations with partners like Novo Nordisk, Teijin, and VISEN Pharmaceuticals.
Key Financial Metrics
| Metric (EUR'000) | 9 Months Ended Sep 30, 2025 | 9 Months Ended Sep 30, 2024 |
|---|---|---|
| Revenue | 472,632 | 189,725 |
| Gross Profit | 401,315 | 159,490 |
| Operating Profit/(Loss) | (146,167) | (279,146) |
| Net Profit/(Loss) | (194,472) | (339,615) |
| Cash and Cash Equivalents | 539,092 | 559,543 (Dec 31, 2024) |
| Total Borrowings | 813,650 | 856,616 (Dec 31, 2024) |
| Derivative Liabilities | 233,761 | 150,670 (Dec 31, 2024) |
Note: Borrowings include Convertible Senior Notes (€426.2M) and Royalty Funding Liabilities (€287.8M). Total Equity is negative at €(174.1)M.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by €282.9 million (149%) year-over-year, driven primarily by the U.S. launch of YORVIPATH in December 2024 and continued growth of SKYTROFA.
- Operating Performance: Operating loss improved by €133.0 million, narrowing from €(279.1)M to €(146.2)M, due to significant revenue expansion partially offset by higher SG&A expenses related to commercial build-out.
- Net Loss Reduction: Net loss decreased by €145.1 million to €(194.5)M. This improvement was aided by a non-cash gain of €35.7 million from the VISEN Pharmaceuticals IPO.
- Financial Expenses: Net finance expenses increased by €13.5 million, primarily due to non-cash remeasurement losses on financial liabilities and currency fluctuations.
- Cash Flow: Cash used in operating activities improved significantly by €199.5 million to €(19.5)M, reflecting improved operating performance and working capital management.
Guidance, Outlook, and Risks
- Regulatory Milestones: The FDA has set a PDUFA goal date of November 30, 2025, for the priority review of TransCon CNP (navepegritide) for achondroplasia. An MAA was submitted to the EMA in October 2025.
- Commercial Expansion: YORVIPATH launched in Japan in November 2025 via partner Teijin. SKYTROFA received FDA approval for adult GHD in July 2025.
- Liquidity: Management believes existing capital resources (€539.1M cash) are sufficient to meet projected requirements for at least 12 months. However, the company maintains a negative equity balance of €(174.1)M, which is permitted under Danish law as the parent company holds positive equity.
- Risks:
- Derivative Liability Volatility: A 10% increase in share price could increase derivative liabilities by €46.1 million, negatively impacting equity and profit.
- Patent Litigation: Ongoing disputes with BioMarin regarding TransCon CNP patents, though a key European patent was revoked by the EPO in October 2025.
- Trade Tariffs: Potential impact of U.S. "Reciprocal Tariffs" on operations, though currently assessed as immaterial for pharmaceuticals.
Investor Verification Checklist
- YORVIPATH U.S. Sales Trajectory: Verify the sustainability of the €290.7M YORVIPATH revenue run-rate following the late 2024 launch.
- TransCon CNP Approval: Monitor the FDA decision expected by November 30, 2025, for the achondroplasia indication.
- Derivative Liability Impact: Assess the sensitivity of the €233.8M derivative liability to future share price movements and its effect on reported net loss.
- Royalty Funding Obligations: Review the repayment schedule for the €287.8M royalty funding liabilities tied to future commercial revenue multiples.
- Equity Position: Confirm the company's ability to maintain liquidity despite the negative consolidated equity balance.